

SAIS NEWSLETTER – OCTOBER 14th, 2021

Dear SAIS members

Please find this week's newsletter. I encourage all members to follow SAIS updates on LinkedIn, Facebook and Twitter to stay up to date with the latest news, events and research.


New SAIS Executive Committee - President to be announced in due course

Theresa	Rossouw
Melinda	Suchard
Clive	Gray
Sabelo	Hadebe
Luyanda	Kwofie
One Bridget	Dintwe
Heena	Ranchod
Catherine	Worsley
Simone	Richardson
Deepthi Raju	Abraham

FUNDING CALLS, CONFERENCES, WEBINARS and ANNOUNCEMENTS

Upcoming In-Person Keystone Symposia – Abstract submission deadline until 28 October, 2021.

<https://keypoint.keystonesymposia.org/features/scholarship-opportunities-abstract-deadlines-for-2022-keystone-symposia-conferences/>



Immunometabolism at the Crossroads of Obesity and Cancer
 Joint Meeting With Tumor Metabolism
 Organizers: Lydia Lynch, Hongbo Chi
 January 16 – 20, 2022 | Fairmont Banff Springs, Banff AB, Canada

Viral Immunity: Basic Mechanisms and Therapeutic Applications
 Joint Meeting With Respiratory Viruses: New Frontiers
 Organizers: Katherine Kedzierska, Paul G. Thomas
 January 17 – 20, 2022 | Keystone Resort, Keystone CO, USA

A Research Reboot of Tuberculosis on the Keystone Symposia 50th Anniversary
 Scientific Organizers: Joseph Keane, Shabaana A. Khader, Thomas J. Scriba and Alan Sher
 Meeting Details: January 23-26, 2022 | Beaver Run Resort, Breckenridge, CO, USA

Antibodies as Drugs

Joint Meeting With Computational Design and Modeling of Biomolecules
Organizers: Pierre Bruhns, Patrick C. Wilson, Esther Breijl, David P. Humphreys
 January 30 – Feb 2, 2022 | Keystone Resort, Keystone CO, USA

Call for Abstracts - Conference of South African Rheumatology Association (SARAA)



SARAA Congress 2022
 Enhancing care in rheumatology
 SARAA 10 – 13 March • Durban



PUBLICATIONS and INTERESTING READS:

'Historic moment' for malaria vaccine

https://www.science.org/content/article/landmark-decision-who-greenlights-rollout-africa-first-malaria-vaccine?utm_source=Nature+Briefing&utm_campaign=caf0465157-briefing-dy-20211007&utm_medium=email&utm_term=0_c9dfd39373-caf0465157-46191682&

Filters could clean SARS-CoV-2 from air

https://www.nature.com/articles/d41586-021-02669-2?utm_source=Nature+Briefing&utm_campaign=caf0465157-briefing-dy-20211007&utm_medium=email&utm_term=0_c9dfd39373-caf0465157-46191682

Anti-SARS-CoV-2 receptor binding domain antibody evolution after mRNA vaccination

<https://www.nature.com/articles/s41586-021-04060-7>

Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses

<https://cancerimmunolres.aacrjournals.org/content/9/10/1158>

Cancer Therapy Doesn't Diminish Vaccine Efficacy

<https://cancerdiscovery.aacrjournals.org/content/early/2021/10/07/2159-8290.CD-NB2021-0387>

Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19

<https://bloodcancerdiscov.aacrjournals.org/content/2/1/9>

Behind the promising first oral COVID drug

https://www.nature.com/articles/d41586-021-02783-1?utm_source=Nature+Briefing&utm_campaign=f713ed03bd-briefing-dy-20211011&utm_medium=email&utm_term=0_c9dfd39373-f713ed03bd-46191682

COVID-19 Delta Variant Tied to More Hospitalizations in Pregnant Patients

https://www.practiceupdate.com/c/124998/2/20/?elsca1=emc_eneews_daily-digest&elsca2=email&elsca3=practiceupdate_rm&elsca4=respiratorymedicine&elsca5=newsletter&rid=NDY1Mzc5NzcwNTYyS0&lid=22920205

mRNA Covid-19 Vaccine Efficacy Among US Healthcare Personnel

<https://www.practiceupdate.com/content/mrna-covid-19-vaccine-efficacy-among-us-healthcare-personnel/124294/37/20/1>

Effectiveness of Moderna, Pfizer-BioNTech, and Janssen Vaccines in Preventing COVID-19 Hospitalizations in Adults

<https://www.practiceupdate.com/content/effectiveness-of-moderna-pfizer-biontech-and-janssen-vaccines-in-preventing-covid-19-hospitalizations-in-adults/124218/37/20/1>

Pulmonary TB associated with increased lung cancer risk in patients with COPD

<https://www.tbonline.info/posts/2021/10/7/pulmonary-tb-associated-increased-lung-cancer-risk/>

BCG: the history and modern-day uses of the TB vaccine

<https://www.tbonline.info/posts/2021/10/4/bcg-history-and-modern-day-uses-tb-vaccine/>

Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study

<https://www.thelancet.com/journals/laninf/article/PIIS1473-3099>

Xpert MTB/XDR for rapid detection of drug-resistant tuberculosis beyond rifampicin

<https://www.thelancet.com/journals/laninf/article/PIIS1473-3099>

JOBS and POSITIONS

2 PhD and 1 postdoc position in translational oncology at the Medical University of Vienna

Medical University of Vienna (MUW) - Vienna, Austria

A post-doctoral and two PhD positions are available in the laboratory of Gergely Szakacs/Agnes Csiszar at the Institute for Cancer Research at the Medical University of Vienna. Our new group is interested in anticancer therapy resistance, especially focusing on breast cancer. We employ a large number of approaches including biochemical and cell biological assays, genetic screens, single-cell sequencing, clinical research and mouse genetics. Pls visit <https://krebsforschung.meduniwien.ac.at/forschung/forschungsschwerpunkte/sicherheit-chemischer-substanzen-und-krebspraevention/gergely-szakacs/>. Please send a cover letter, CV, a brief summary of research accomplishments, a statement of career goals (postdocs) and contact information of three references to reka.kertesz@meduniwien.ac.at. Deadline for Applications: November 15, 2021.

Associate or Senior Editor, Immunology (38922)

Do you love science but feel that a career at the bench isn't enough to satisfy your desire to learn more about the natural world? Do you enjoy reading papers outside your chosen area of research? If the answer is 'yes', you could be the person we're looking for to join the editorial team of *Nature*. **Please apply by sending** your CV, covering letter (including your class of degree, a brief account of your research and other relevant experience, and details of your current salary) and a concise discussion of recent scientific developments



which you have found particularly exciting (stating why). Please visit <https://career5.successfactors.eu/sfcareer/jobreqcareer?jobId=38922&company=C0001215517P>. The closing date for applications is 14th October 2021.

Flow Cytometry Technical Specialist – HVTN, Cape Town

The Flow Cytometry Technical Specialist will be responsible for independently overseeing the flow cytometry core at CHIL and conducting assays in the lab. S/he will be responsible for overseeing flow cytometer maintenance, standardisation, and quality control as well as for providing training and supervision of lab staff on the instruments. She/he will assist with the development and optimization of novel antibody staining panels and assays. S/he will perform laboratory assays and data analysis according to GCLP principles and practices. S/he will report findings in oral and written formats and at specialized scientific meetings. Extensive flow cytometry experience as well as specialized laboratory skills and knowledge are applied in this position to fulfil complex research responsibilities. Discretion and judgment are used in the performance of daily duties. Senior level position requiring a high degree of specialized training, both theoretical and practical, in the application and conduct of best practices in flow cytometry. • BTech, BSc, BHSc, or MSc degree with at least 10 years of wet lab experience in immunology, molecular biology, virology or related field, including at least 4 years of experience managing a flow cytometry core. Interested applicants should send a direct email to Bongvi Vilakazi (svilakaz@hcrisa.org.za).

IMPORTANT LINKS

To renew your SAIS Membership please visit: <https://saimmunology.org.za/membership.htm>

Please don't forget to send me any information on funding opportunities, meetings, workshops and/or conferences, so I can publish it. Additionally, if you are recruiting/hiring, I am more than happy to advertise it on LinkedIn/twitter and in the newsletter.

Thank you.

Kind regards

Clement Adu-Gyamfi